This company is no longer active
Eiger BioPharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Eiger BioPharmaceuticals has a total shareholder equity of $-14.5M and total debt of $41.1M, which brings its debt-to-equity ratio to -284.4%. Its total assets and total liabilities are $38.8M and $53.3M respectively.
Key information
-284.4%
Debt to equity ratio
US$41.12m
Debt
Interest coverage ratio | n/a |
Cash | US$25.84m |
Equity | -US$14.46m |
Total liabilities | US$53.28m |
Total assets | US$38.83m |
Recent financial health updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20Financial Position Analysis
Short Term Liabilities: EIGR.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EIGR.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EIGR.Q has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EIGR.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if EIGR.Q has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EIGR.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.